Sirexatamab by Leap Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval

Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Hepatocellular Carcinoma.

Related Keywords

Massachusetts ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Australia ,New Zealand ,Japan , ,Beigene Ltd ,Globaldata Pharmaceutical Intelligence Center ,Leap Therapeutics ,Hepatocellular Carcinoma ,Phase Transition Success Rate Model ,Pharmaceutical Intelligence ,